Eli Lilly’s Secret Obesity Drug Access

Eli Lilly secretly gave a 79-year-old man exclusive access to its experimental obesity drug retratrutide—a powerful weight-loss treatment rivaling bariatric surgery—through the FDA’s compassionate use program, sparking wild speculation after Trump’s stock investments and dinner with Lilly’s CEO fueled rumors. The company insists the decision followed strict criteria and regulations, but the move underscores the urgent demand for new obesity treatments and the murky ethics of experimental drug access. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/eaa74f4a48b3e45c